K21
Conditions
Interventions
Group 1: Patients who received an EGD and a ph MII at the same time between 2015 and 2022 and who had diagnosed an erosive gastroesophageal reflux disease, a non-erosive gastroesophageal reflux disea
Sponsors
Universitätskinderklinik Bochum
Eligibility
Sex/Gender
All
Age
No minimum to 17 Years
Inclusion criteria
Inclusion criteria: Patients who received an EGD and a pH MII under sedation at the same time between 2015 and 2022 and who had aerosive gastroesophageal reflux disease or a non-erosive gastroesophageal reflux disease diagnosed or a macroscopically normal EGD and a normal pH MII
Exclusion criteria
Exclusion criteria: Proton pump inhibitor, antacid or steroid therapy in the four weeks before the endoscopic diagnosis Presence of esophageal strictures Presence of esophageal motility disorder (e.g. achalasia) Presence of eosinophilic esophagitis Presence of thrush esophagitis Patients with corrected esophageal atresia Patients with psychomotor disabilities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in the PSPW index between children and adolescents with erosive gastroesophageal reflux disease, with non-erosive gastroesophageal reflux disease and a control group | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences of MNBI and simplified MNBI between children and adolescents with erosive gastroesophageal reflux disease, with non-erosive gastroesophageal reflux disease and a control group Correlation of the novel ph MII parameters with the established standardized evaluated parameters Differences of the novel pH MII parameters in children =12 months and children and adolescents >12 months and =18 years | — |
Countries
Germany
Contacts
Public ContactAnjona Schmidt-Choudhury
Universitätskinderklinik Bochum
Outcome results
None listed